Six-month hematological response to second-line crossover treatment
| Second-line crossover treatment (NR only) . | IST crossover group (n = 12), n (%) . | IST + ELTR crossover group (n = 18), n (%) . | Difference in % (95% CI) . | P value . |
|---|---|---|---|---|
| OR | 2 (17) | 11 (61) | 44 (14 to 75) | .016 |
| CR | 1 (8) | 2 (11) | 3 (−19 to 24) | .999 |
| PR | 1 (8) | 9 (50) | — | — |
| Median time to overall response, days (range) | Not reached (55 to 70) | 118 (26 to 182) | — | .029 |
| Second-line crossover treatment (NR only) . | IST crossover group (n = 12), n (%) . | IST + ELTR crossover group (n = 18), n (%) . | Difference in % (95% CI) . | P value . |
|---|---|---|---|---|
| OR | 2 (17) | 11 (61) | 44 (14 to 75) | .016 |
| CR | 1 (8) | 2 (11) | 3 (−19 to 24) | .999 |
| PR | 1 (8) | 9 (50) | — | — |
| Median time to overall response, days (range) | Not reached (55 to 70) | 118 (26 to 182) | — | .029 |